COMBINATION THERAPY OF PACLITAXEL AND UVB1 IN HNSCC AND TNBC CELLS

IBARRA, A.; CLEMENTE, V.; SCHWEITZER, K.; COLÓ, G.P.; ALONSO, E.N.; FERMENTO, M.E.; FACCHINETTI, M.M.; FERRONATO, M.J.; CURINO, A.C.

Mar del Plata

Congreso; Reunión Anual de Sociedades de Biociencia; 2023

Head and Neck Squamous Cell Carcinoma (HNSCC) and Triple Negative Breast Cancer (TNBC) are heterogeneous and aggressive tumors with high mortality and difficult clinical management. Conventional chemotherapy remains as the main clinical management with the concomitant undesirable side effects for patients and time-limited positive responses. Further research is needed to find novel therapeutic strategies that prolong the patient survival and ensure a better quality of life. The aim of the present study was to evaluate the antitumor potential of the combination of the conventional chemotherapeutic agent Paclitaxel (PTX) with the non-hypercalcemic Calcitriol analog UVB1 in HNSCC and TNBC cells. Cell viability was evaluated by crystal violet assays in human HN13 and HN12 HNSCC and murine 4T1 TNBC cell lines treated with vehicle, UVB1, PTX or combination of drugs. The results show that UVB1 (1μM) with low concentrations of PTX displayed a greater reduction in viability with respect to control and monotherapies in all cell lines tested (120h of treatment, p